Review Article: Breast CancerAspirin and NSAIDs for breast cancer chemopreventionYiannakopoulou, Eugenia ChAuthor Information Department of Medical Laboratories, Faculty of Health and Caring Professions, Technological Educational Institute of Athens, Athens, Greece Correspondence to Eugenia Ch Yiannakopoulou, MD, MSc, PhD, Eleutheriou Benizelou 106 Kallithea, 17676 Athens, Greece Tel: +30 210 956 3791, +30 210 956 3761; fax: +30 210 5385605 e-mail: [email protected] Received March 3, 2014 Accepted October 8, 2014 European Journal of Cancer Prevention: September 2015 - Volume 24 - Issue 5 - p 416-421 doi: 10.1097/CEJ.0000000000000098 Buy Metrics Abstract Novel treatment strategies are needed for breast cancer chemoprevention. Tamoxifen is the only drug approved for the chemoprevention of estrogen receptor-positive breast cancer. However, to date, no treatment exists for the chemoprevention of estrogen receptor-negative breast cancer. NSAID use is associated with a reduced risk of breast cancer. However, the biological mechanisms underlying the effect of NSAID on breast cancer are not well defined. NSAIDs inhibit cyclooxygenases, thus preventing the formation of prostaglandins, prostacyclin, and thromboxane. NSAIDs also exert other biological effects, including generation of reactive oxygen species and inhibition of nuclear factor-κB-mediated signals. This review synthesizes the evidence on the COX-2-independent mechanisms of action of aspirin, salicylates, and other NSAIDs on breast cancer. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.